Moderna's Newfound War Chest Opens Door for 4 Strategic Acquisition Targets - 24/7 Wall St. Moderna's Newfound War Chest Opens Door for 4 Strategic Acquisition Targets Moderna's 177% stock surge to a ~$70B market cap makes ABUS a prime target, as buying it eliminates $1.3B in LNP patent exposure. NTLA's Phase 3 lonvo-z showed 87% fewer hereditary angioedema attacks, while EDIT offers cardiometabolic pipeline access at just a $442M market cap. The most widely read finance newsletter on Substack isn't publish ...